Expression Of TIM-3 And CEACAM-1 In Bladder Urothelial Carcinoma ( Immunohistochmical And Histopathological Study )
Mahmoud, A., Ali Daoud, S., Ismail Moustafa, W., Sayed, O., Bayoumi Ibrahim, B., Mohamed Sayed, M., Abdelrahman Mohammed, S. (2021). Expression Of TIM-3 And CEACAM-1 In Bladder Urothelial Carcinoma ( Immunohistochmical And Histopathological Study ). EKB Journal Management System, 2(2), 227-249. doi: 10.21608/ejmr.2021.175726
Abla Sayed Mahmoud; Sahar Ali Daoud; Wesam Ismail Moustafa; Osama Sayed; Badawia Bayoumi Ibrahim; Marwa Mohamed Sayed; Sarah Abdelrahman Mohammed. "Expression Of TIM-3 And CEACAM-1 In Bladder Urothelial Carcinoma ( Immunohistochmical And Histopathological Study )". EKB Journal Management System, 2, 2, 2021, 227-249. doi: 10.21608/ejmr.2021.175726
Mahmoud, A., Ali Daoud, S., Ismail Moustafa, W., Sayed, O., Bayoumi Ibrahim, B., Mohamed Sayed, M., Abdelrahman Mohammed, S. (2021). 'Expression Of TIM-3 And CEACAM-1 In Bladder Urothelial Carcinoma ( Immunohistochmical And Histopathological Study )', EKB Journal Management System, 2(2), pp. 227-249. doi: 10.21608/ejmr.2021.175726
Mahmoud, A., Ali Daoud, S., Ismail Moustafa, W., Sayed, O., Bayoumi Ibrahim, B., Mohamed Sayed, M., Abdelrahman Mohammed, S. Expression Of TIM-3 And CEACAM-1 In Bladder Urothelial Carcinoma ( Immunohistochmical And Histopathological Study ). EKB Journal Management System, 2021; 2(2): 227-249. doi: 10.21608/ejmr.2021.175726

Expression Of TIM-3 And CEACAM-1 In Bladder Urothelial Carcinoma ( Immunohistochmical And Histopathological Study )

Egyptian Journal of Medical Research
Article 16, Volume 2, Issue 2 - Serial Number 1, June 2021, Page 227-249  XML PDF (2.28 MB)
Document Type: Original Article
DOI: 10.21608/ejmr.2021.175726
View on SCiNiTO View on SCiNiTO
Authors
Abla Sayed Mahmoud1; Sahar Ali Daoud1; Wesam Ismail Moustafa1; Osama Sayed2; Badawia Bayoumi Ibrahim3; Marwa Mohamed Sayed1; Sarah Abdelrahman Mohammed1
1Pathology department, Faculty of medicine, Beni- Suef University, Beni- Suef, Egypt
2Urology department, Faculty of medicine, Beni- Suef University, Beni-Suef, Egypt
3Pathology department, Faculty of medicine, Cairo University, Cairo, Egypt
Abstract
Background and objectives: Urothelial carcinoma is now considered to be the most important tumor of the urinary bladder in Egypt especially after decreased prevalence of schistosomiasis.  Due to few available therapeutic approaches and partial success in improving patients' survival, novel immunotherapeutic agents such as immune checkpoint inhibitors become a promising hope especially after PD-1 and CTLA-4 being clinically relevant. TIM-3 which is another immune checkpoints molecule is recently appeared to be associated with immune suppression in many tumors and has been reported to be aberrantly expressed in several human malignancies including urothelial carcinoma. One of the TIM-3 discovered ligands is CEACAM-1. The latter has been linked to malignancy progression and metastatic spread and has been expressed in many tumor types. The aim of our work is to evaluate the expression of TIM-3 and CEACAM-1 in bladder urothelial carcinoma and analyse their correlations with clinical and pathological related factors. Methods: Different TIM-3 and CEACACM-1 expressions were evaluated in immunohistochemically stained paraffin embedded sections from 60 Egyptian patients with bladder urothelial carcinoma. Expression was correlated with the available clinical and pathological data. Results: Both TIM-3 and CEACAM-1 were expressed in cancer cells, tumor infiltrating lymphocytes and endothelial cells. TIM-3 expression by cancer cells showed significant correlation with tumor necrosis and TIM-3 expression by TILs.  TIM-3 expression by TILs significantly related to TIM-3 expression by endothelial cells. Endothelial CEACAM-1 positivity significantly correlated to tumor grade, associated inflammation, tumor necrosis, muscle invasion and tumor differentiation. CEACAM-1 expression by TILs was significantly related to its expression in tumor cells and absent vascular emboli. Regarding correlations between the both studied markers, expression of TIM-3 by cancer cells was significantly correlated to CEACAM-1 expression by both TILs and endothelial cells. In addition, TIM-3 and CEACAM-1 expressions by TILs were significantly positively correlated. Conclusion: The expressions of TIM-3 and CEACAM-1 in urothelial cancer cells and TILs suggest a potential role for these molecules in cancer development and progression and introduce them as a novel targets in bladder cancer therapy. In addition, endothelial CEACAM-1 expression could be a marker of tumor progression and invasiveness.
Keywords
TIM-3; CEACAM-1; urothelial carcinoma; immunotherapy
References
  1. Kim, T. J., Cho, K. S., & Koo, K. C. (2020). Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review. Cancers, 12(1), 192.
  2. Wagih, M., & Kamel, M. (2020). Evaluation of androgen receptor status in urothelial carcinoma of the urinary bladder in Egyptian patients: an immunohistochemical study. African Journal of Urology, 26(1), 1-5.
  3. Tripathi, A., & Plimack, E. R. (2018). Immunotherapy for urothelial carcinoma: current evidence and future directions. Current urology reports, 19(12), 109.
  4. Li, H., Zhang, Q., Shuman, L., Kaag, M., Raman, J. D., Merrill, S., ... & Chen, G. (2020). Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes. Scientific reports, 10(1), 1-9.
  5. Kim, H. D., & Park, S. H. (2019). Immunological and clinical implications of immune checkpoint blockade in human cancer. Archives of pharmacal research, 1-15.
  6. Yang, M., Yu, Q., Liu, J., Fu, W., Cao, Y., Yu, L., ... & Wang, Y. (2015). T‐cell immunoglobulin mucin‐3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival. Journal of surgical oncology, 112(4), 430-435.
  7. Huang, Y. H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., ... & Clayton, K. L. (2016). CEACAM1 regulates TIM-3-mediated tolerance and exhaustion (vol 517, pg 386, 2015). Nature, 536(7616), 359-359.
  8. Tilki, D., Singer, B. B., Shariat, S. F., Behrend, A., Fernando, M., Irmak, S., ... & Ergün, S. (2010). CEACAM1: a novel urinary marker for bladder cancer detection. European urology, 57(4), 648-654.
  9. Zhang, Y., Cai, P., Li, L., Shi, L., Chang, P., Liang, T., ... & Hu, L. (2017). Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients. International immunopharmacology, 43, 210-218.
  10. Wolf, Y., Anderson, A. C., & Kuchroo, V. K. (2019). TIM3 comes of age as an inhibitory receptor. Nature Reviews Immunology, 1-13.
  11.  Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., & Ulbright, T. M. (2016). The 2016 WHO classification of tumours of the urinary system and male genital organs—part A: renal, penile, and testicular tumours. European urology, 70(1), 93-105.
  12. Bochner, B.H., Hansel, D.E., Efstathiou, J.A., Konety, B., Lee, C.T., Mckiernan, J.M., Plimack, E.R., Reuter, V.E., Sridhar, S., Vikram, R., Stadler, W. M. (2017). AJCC Cáncer Staging Manual. In M. B. Amin (Ed.), AJCC Cancer Staging Manual (8th ed., p. 758, 759, 760, 763,764). Springer.
  13. Shan, B., Man, H., Liu, J., Wang, L., Zhu, T., Ma, M., ... & Li, P. (2016). TIM-3 promotes the metastasis of esophageal squamous cell carcinoma by targeting epithelial-mesenchymal transition via the Akt/GSK-3β/Snail signaling pathway. Oncology reports, 36(3), 1551-1561.
  14. Holland, B. C., Sood, A., Delfino, K., Dynda, D. I., Ran, S., Freed, N., & Alanee, S. (2019). Age and sex have no impact on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy. Cancer Immunology, Immunotherapy, 68(6), 991-997.
  15. Wang, N., Feng, Y., Wang, Q., Liu, S., Xiang, L., Sun, M., ... & Wei, F. (2014). Neutrophils infiltration in the tongue squamous cell carcinoma and its correlation with CEACAM1 expression on tumor cells. PloS one, 9(2).
  16. Donin, N. M., Lenis, A. T., Holden, S., Drakaki, A., Pantuck, A., Belldegrun, A., & Chamie, K. (2017). Immunotherapy for the treatment of urothelial carcinoma. The Journal of urology, 197(1), 14-22.
  17. He, Y., Cao, J., Zhao, C., Li, X., Zhou, C., & Hirsch, F. R. (2018). TIM-3, a promising target for cancer immunotherapy. OncoTargets and therapy, 11, 7005.
  18. Das, M., Zhu, C., & Kuchroo, V. K. (2017). Tim‐3 and its role in regulating anti‐tumor immunity. Immunological reviews, 276(1), 97-111.
  19. Qin, S., Dong, B., Yi, M., Chu, Q., & Wu, K. (2020). Prognostic values of TIM-3 expression in patients with solid tumors: a meta-analysis and databa
  20. Xu, Y., Jiang, X., & Huang, Y. (2017). T-cell immunoglobulin and mucin-domain containing-3 in malignant cancers. Translational Cancer Research, 6(3), 613-619.
  21. Li, J., Liu, X., Duan, Y., Liu, Y., Wang, H., Lian, S., Zhuang, G., & Fan, Y. (2017). Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas. Medical science monitor : international medical journal of experimental and clinical research, 23, 3593–3602.
  22. Zhang, W., Feng, H., Chen, Q., Lu, X., & Ge, J. (2018). The functional potency of natural killer cells in response to IL-2/IL-15/IL-21 stimulation is limited by a concurrent upregulation of Tim-3 in bladder cancer. Experimental cell research, 372(2), 92-98.
  23. Audenet, F., Farkas, A. M., Anastos, H., Galsky, M. D., Bhardwaj, N., & Sfakianos, J. P. (2018). Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer. World journal of urology, 36(11), 1741-1748.
  24. Wu, F. H., Yuan, Y., Li, D., Lei, Z., Song, C. W., Liu, Y. Y., ... & Zhang, G. M. (2010). Endothelial cell-expressed Tim-3 facilitates metastasis of melanoma cells by activating the NF-κB pathway. Oncology reports, 24(3), 693-699.
  25. Huang, X., Bai, X., Cao, Y., Wu, J., Huang, M., Tang, D., ... & Zhou, X. (2010). Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. Journal of Experimental Medicine, 207(3), 505-520.
  26. Shang, Y., Li, Z., Li, H., Xia, H., & Lin, Z. (2013). TIM-3 expression in human osteosarcoma: Correlation with the expression of epithelial‑mesenchymal transition-specific biomarkers. Oncology letters, 6(2), 490-494.
  27. Oliveira-Ferrer, L., Tilki, D., Ziegeler, G., Hauschild, J., Loges, S., Irmak, S., ... & Ergün, S. (2004). Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. Cancer research, 64(24), 8932-8938.‏
  28. Oliveira-Ferrer, L., Goswami, R., Galatenko, V., Ding, Y., Eylmann, K., Legler, K., ... & Milde-Langosch, K. (2018). Prognostic impact of CEACAM1 in node-negative ovarian cancer patients. Disease markers, 2018.
  29. Richards, C. H., Roxburgh, C. S. D., Anderson, J. H., McKee, R. F., Foulis, A. K., Horgan, P. G., & McMillan, D. C. (2012). Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer. British journal of surgery, 99(2), 287-294.
  30. Calinescu, A., Turcu, G., Nedelcu, R. I., Brinzea, A., Hodorogea, A., Antohe, M., ... & Ion, D. A. (2018). On the dual role of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in human malignancies. Journal of immunology research, 2018.
  31. Beauchemin, N., & Arabzadeh, A. (2013). Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer and Metastasis Reviews, 32(3-4), 643-671.
  32. Li, J., Liu, X., Duan, Y., Wang, H., Su, W., Wang, Y., ... & Fan, Y. (2018). Abnormal expression of circulating and tumor-infiltrating carcinoembryonic antigen-related cell adhesion molecule 1 in patients with glioma. Oncology letters, 15(3), 3496-3503.
  33. Gray-Owen, S. D., & Blumberg, R. S. (2006). CEACAM1: contact-dependent control of immunity. Nature Reviews Immunology, 6(6), 433.
  34. Markel, G., Seidman, R., Stern, N., Cohen-Sinai, T., Izhaki, O., Katz, G., ... & Mandelboim, O. (2006). Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. The Journal of Immunology, 177(9), 6062-6071.
  35. Li, Y., & Shively, J. E. (2013). CEACAM1 regulates Fas-mediated apoptosis in Jurkat T-cells via its interaction with β-catenin. Experimental Cell Research, 319(8), 1061–1072.
  36. Ueshima, C., Kataoka, T. R., Takei, Y., Hirata, M., Sugimoto, A., Hirokawa, M., ... & Haga, H. (2017). CEACAM 1 long isoform has opposite effects on the growth of human mastocytosis and medullary thyroid carcinoma cells. Cancer medicine, 6(4), 845-856.
  37. Linhares, A. D. S., Kellner, F., Jutz, S., Zlabinger, G. J., Gabius, H. J., Huppa, J. B., ... & Steinberger, P. (2020). TIM‐3 and CEACAM1 do not interact in cis and in trans. European Journal of Immunology.

 

Statistics
Article View: 385
PDF Download: 306